Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -56.59%31.78M | -12.02%23.71M | -128.98%-5.21M | -28.33%11.14M | -83.20%2.14M | 57.75%73.21M | 59.39%26.95M | 301.32%17.99M | -3.45%15.55M | 42.69%12.72M |
Net income from continuing operations | -6.49%36.13M | 35.32%12.98M | -66.93%3.66M | 14.33%12.57M | -1.06%6.93M | 563.93%38.64M | 45.39%9.59M | 123.70%11.05M | 147.29%10.99M | 168.88%7M |
Operating gains losses | 412.29%1.88M | 843.18%2.67M | -430.02%-1.76M | 106.57%37K | 538.50%934K | -139.68%-602K | 75.89%-359K | -71.93%533K | -165.93%-563K | -184.19%-213K |
Depreciation and amortization | 4.34%16.42M | 22.17%4.1M | -9.65%3.76M | 16.70%4.62M | -7.49%3.94M | 0.55%15.74M | -22.62%3.35M | 5.74%4.17M | 3.21%3.96M | 20.23%4.26M |
Deferred tax | -882.86%-2.06M | 726.26%9.56M | -845.36%-9.71M | -1,947.93%-3.46M | 744.81%1.55M | 80.68%-210K | -191.55%-1.53M | -29.15%1.3M | -107.17%-169K | 102.63%183K |
Other non cash items | 6,683.67%6.65M | 629.32%970K | 8,675.00%2.11M | 10,855.00%2.15M | 3,743.59%1.42M | -97.97%98K | -89.06%133K | -98.74%24K | -101.25%-20K | -135.14%-39K |
Change In working capital | -459.74%-36.37M | -164.75%-8.69M | -296.08%-5.36M | -926.44%-7.14M | -1,105.80%-15.18M | 180.30%10.11M | 771.36%13.42M | 89.35%-1.35M | -1,015.79%-696K | 16.57%-1.26M |
-Change in receivables | -477.19%-24.9M | -889.91%-25.06M | 184.99%3.55M | -313.81%-6.08M | -70.29%2.7M | 157.23%6.6M | 138.39%3.17M | -14,814.29%-4.18M | 5.16%-1.47M | 636.03%9.08M |
-Change in inventory | 198.00%10.02M | 528.51%12.61M | -1,934.57%-4.94M | 108.72%537K | 131.18%1.82M | -979.78%-10.22M | -75.97%2.01M | 95.76%-243K | -511.77%-6.16M | -97.23%-5.83M |
-Change in prepaid assets | -1,842.38%-5.87M | -160.27%-1.71M | 25.46%-4.87M | -133.47%-1.32M | 464.75%2.03M | 96.08%-302K | 132.53%2.83M | -148.21%-6.53M | 763.10%3.95M | -117.61%-556K |
-Change in payables and accrued expense | -211.33%-15.62M | 1.13%5.47M | -90.60%902K | -109.24%-275K | -450.23%-21.72M | 155.49%14.03M | -46.71%5.41M | 322.34%9.59M | 1,010.40%2.98M | -21,833.33%-3.95M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -56.59%31.78M | -12.02%23.71M | -128.98%-5.21M | -28.33%11.14M | -83.20%2.14M | 57.75%73.21M | 59.39%26.95M | 301.32%17.99M | -3.45%15.55M | 42.69%12.72M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -2,161.13%-147.43M | 47.30%-1.31M | 46.26%-991K | -54.08%-2.49M | -24,492.41%-142.64M | 89.07%-6.52M | -50.27%-2.48M | -296.56%-1.84M | 95.60%-1.62M | 97.20%-580K |
Net PPE purchase and sale | 13.91%-5.61M | 47.30%-1.31M | 46.26%-991K | -21.94%-1.97M | -131.55%-1.34M | -59.69%-6.52M | -116.42%-2.48M | -296.56%-1.84M | -6.24%-1.62M | 38.95%-580K |
Net business purchase and sale | ---141.81M | --0 | --0 | ---520K | ---141.29M | --0 | --0 | --0 | --0 | --0 |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -2,161.13%-147.43M | 47.30%-1.31M | 46.26%-991K | -54.08%-2.49M | -24,492.41%-142.64M | 89.07%-6.52M | -50.27%-2.48M | -296.56%-1.84M | 95.60%-1.62M | 97.20%-580K |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 717.53%152.67M | 250.44%9.84M | -209.62%-7.05M | 252.86%10.1M | 1,602.59%139.79M | -201.06%-24.72M | 3.10%-6.54M | -159.07%-2.28M | -116.38%-6.6M | 28.20%-9.3M |
Net issuance payments of debt | 937.00%83.9M | 539.11%15.65M | -289.32%-5.68M | -42.60%-3.57M | 3,200.00%77.5M | 9.52%-10.02M | 2.36%-3.56M | 39.12%-1.46M | 0.56%-2.5M | 0.68%-2.5M |
Net common stock issuance | --91.78M | --0 | --0 | --18.24M | --73.54M | --0 | --0 | --0 | --0 | --0 |
Cash dividends paid | -16.18%-13.95M | -18.16%-3.55M | -18.20%-3.55M | -18.16%-3.55M | -10.15%-3.29M | -4.32%-12.01M | -0.64%-3.01M | -0.60%-3.01M | -8.05%-3.01M | -8.58%-2.99M |
Net other financing activities | -236.63%-9.06M | -6,951.52%-2.26M | -0.09%2.19M | 6.29%-1.03M | -108.54%-7.96M | 70.99%-2.69M | 130.28%33K | -16.29%2.19M | 73.20%-1.1M | 50.36%-3.82M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 717.53%152.67M | 250.44%9.84M | -209.62%-7.05M | 252.86%10.1M | 1,602.59%139.79M | -201.06%-24.72M | 3.10%-6.54M | -159.07%-2.28M | -116.38%-6.6M | 28.20%-9.3M |
Net cash flow | ||||||||||
Beginning cash position | 93.64%87.69M | 33.97%92.99M | 89.85%105.9M | 80.25%87.05M | 93.64%87.69M | 33.76%45.29M | 90.95%69.41M | 93.27%55.78M | 388.95%48.29M | 33.76%45.29M |
Current changes in cash | -11.79%37.02M | 79.79%32.24M | -195.57%-13.26M | 155.90%18.75M | -125.11%-713K | 273.17%41.97M | 110.68%17.93M | 76.17%13.87M | -62.70%7.33M | 111.46%2.84M |
Effect of exchange rate changes | -48.86%224K | -185.84%-297K | 242.08%341K | -34.97%106K | -56.21%74K | 139.34%438K | -18.40%346K | 37.66%-240K | 124.92%163K | -78.82%169K |
End cash Position | 42.47%124.93M | 42.47%124.93M | 33.97%92.99M | 89.85%105.9M | 80.25%87.05M | 93.64%87.69M | 93.64%87.69M | 90.95%69.41M | 93.27%55.78M | 388.95%48.29M |
Free cash flow | -60.73%26.11M | -8.36%22.42M | -138.58%-6.23M | -34.49%9.12M | -93.35%794K | 58.61%66.48M | 59.39%24.47M | 301.87%16.15M | -4.49%13.92M | 49.90%11.94M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |